These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12581567)

  • 21. 18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of Non-Small Cell Lung Cancer: A Prospective Study.
    Promteangtrong C; Kunawudhi A; Phadungrerk R; Iamsa-art C; Chotipanich C
    J Med Assoc Thai; 2015 Oct; 98(10):1010-8. PubMed ID: 26638593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients.
    Kim SJ; Hwang SH; Kim IJ; Lee MK; Lee CH; Lee SY; Lee EY
    J Exp Clin Cancer Res; 2010 Jun; 29(1):69. PubMed ID: 20540786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
    Collaud S; Lardinois D; Tischler V; Steinert HC; Stahel R; Weder W
    Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of (18)F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: a retrospective study.
    Na II; Cheon GJ; Choe DH; Byun BH; Kang HJ; Koh JS; Park JH; Baek H; Ryoo BY; Lee JC; Yang SH
    Lung Cancer; 2008 Apr; 60(1):69-74. PubMed ID: 18029051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
    Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
    Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
    Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
    J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma.
    Cerfolio RJ; Ojha B; Mukherjee S; Pask AH; Bass CS; Katholi CR
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):938-44. PubMed ID: 12698159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymph node staging in lung cancer using [18F]FDG-PET.
    Halter G; Buck AK; Schirrmeister H; Aksoy E; Liewald F; Glatting G; Neumaier B; Mühling B; Nüssle-Kügele K; Hetzel M; Sunder-Plassmann L; Reske SN
    Thorac Cardiovasc Surg; 2004 Apr; 52(2):96-101. PubMed ID: 15103582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).
    Miele E; Spinelli GP; Tomao F; Zullo A; De Marinis F; Pasciuti G; Rossi L; Zoratto F; Tomao S
    J Exp Clin Cancer Res; 2008 Oct; 27(1):52. PubMed ID: 18928537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
    Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
    Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
    Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
    Schmid RA; Hautmann H; Poellinger B; Kellner W; Moisseev A; Brinkbaeumer K; Weiss M; Hahn K; Dresel S
    Nucl Med Commun; 2003 Jan; 24(1):37-45. PubMed ID: 12501018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: the impact of 2-(18)F-fluoro-2-deoxy-D-glucose positron emission tomogram mediastinal staging.
    Barnett S; Baste JM; Murugappan K; Tog C; Berlangieri S; Scott A; Seevanayagam S; Knight S
    Eur J Cardiothorac Surg; 2011 Jan; 39(1):96-101. PubMed ID: 20580245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings.
    Konishi J; Yamazaki K; Tsukamoto E; Tamaki N; Onodera Y; Otake T; Morikawa T; Kinoshita I; Dosaka-Akita H; Nishimura M
    Respiration; 2003; 70(5):500-6. PubMed ID: 14665776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
    Aquino SL; Asmuth JC; Alpert NM; Halpern EF; Fischman AJ
    J Comput Assist Tomogr; 2003; 27(4):479-84. PubMed ID: 12886128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.
    Gómez-Caro A; Garcia S; Reguart N; Arguis P; Sanchez M; Gimferrer JM; Marrades R; Lomeña F
    Eur J Cardiothorac Surg; 2010 May; 37(5):1168-74. PubMed ID: 20116273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.